on Eckert & Ziegler Strahlen- Und Medizintechnik AG (isin : DE0005659700)
Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement
Berlin, 5 December 2024. Eckert & Ziegler, a leading provider of medical isotopes, and Ariceum Therapeutics, a biotech company specializing in radiopharmaceuticals, have announced a global supply agreement. This collaboration centers on the medical radionuclides Actinium-225 (Ac-225) and Lutetium-177 (Lu-177).
The partnership aims to address the limited availability of Ac-225, crucial for Ariceum's innovative cancer treatment pipeline. Eckert & Ziegler will supply necessary quantities of non-carrier-added Ac-225 and Lu-177 for clinical and commercial use of Ariceum’s lead drug, satoreotide.
This agreement marks a significant advancement in the development of precision radiotherapeutics, hoping to enhance treatment for difficult-to-treat cancers.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news